ИЗУЧЕНИЕ СОВРЕМЕННЫХ МЕТОДОВ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА

Subject Terms: аллергический ринит, лечение, антигистаминные препараты, глюкокортикостероиды, иммунотерапия, биопрепараты, лейкотриены, качество жизни, воспаление

ИЗУЧЕНИЕ СОВРЕМЕННЫХ МЕТОДОВ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА

Subject Terms: аллергический ринит, лечение, антигистаминные препараты, глюкокортикостероиды, иммунотерапия, биопрепараты, лейкотриены, качество жизни, воспаление

Basic therapy for chronic non-infectious dermatoses of the anogenital region ; Базисная терапия при хронических неинфекционных дерматозах аногенитальной области

Authors: I. O. Smirnova, O. N. Smirnova, I. A. Fedorova, P. D. Ptashnikova, И. О. Смирнова, О. Н. Смирнова, И. А. Федорова, П. Д. Пташникова

Source: Meditsinskiy sovet = Medical Council; № 4 (2025); 53-58 ; Медицинский Совет; № 4 (2025); 53-58 ; 2658-5790 ; 2079-701X

Subject Terms: противовоспалительное действие, anogenital region, baseline therapy, skin barrier, dexpanthenol, glucocorticosteroids, treatment, pruritus, clinical manifestations, anti-inflammatory effect, аногенитальная область, базисная терапия, кожный барьер, декспантенол, глюкокортикостероиды, лечение, зуд

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/9024/7841; Lewin MR, Hick RW, Selim MA. Lichenoid Dermatitis of the Vulva: Diagnosis and Differential Diagnosis for the Gynecologic Pathologist. Adv Anat Pathol. 2017;24(5):278–293. https://doi.org/10.1097/PAP.0000000000000160.; Day T, Mauskar M, Selk A (eds.). Lichen sclerosus: ISSVD practical guide to diagnosis and management. Ad Médic, Lda.; 2024. 212 p. https://doi.org/10.59153/adm.ls.001.; Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther. 2021;11(3):833–844. https://doi.org/10.1007/s13555-021-00536-6.; Corazza M, Toni G, Virgili A, Borghi A. Plasma cell vulvitis: further confirmation of the diagnostic utility of dermoscopy. Int J Dermatol. 2018;57(12):e164-e165. https://doi.org/10.1111/ijd.14233.; Yeung J, Pauls RN. Anatomy of the Vulva and the Female Sexual Response. Obstet Gynecol Clin North Am. 2016;43(1):27–44. https://doi.org/10.1016/j.ogc.2015.10.011.; Смирнова ИО (ред.). Неинфекционные дерматозы вульвы: диагностика, лечение: иллюстрированное руководство для врачей. М.: ГЭОТАР-Медиа; 2021. 240 с. https://doi.org/10.33029/9704-6008-5-NDV-1-240.; Nunns D, Mandal D. The chronically symptomatic vulva: prevalence in primary health care. Genitourin Med. 1996;72(5):343–344. https://doi.org/10.1136/sti.72.5.343.; Raef HS, Elmariah SB. Vulvar Pruritus: A Review of Clinical Associations, Pathophysiology and Therapeutic Management. Front Med. 2021;8:649402. https://doi.org/10.3389/fmed.2021.649402.; Neill SM, Lewis FM, Tatnall FM, Cox NH; British Association of Dermatologists. British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163(4):672–682. https://doi.org/10.1111/j.1365-2133.2010.09997.x.; Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891.; Lifits-Podorozhansky YM, Podorozhansky Y, Hoffstetter S, Gavard JA. Role of vulvar care guidelines in the initial management of vulvar complaints. J Low Genit Tract Dis. 2012;16(2):88–91. https://doi.org/10.1097/LGT.0b013e318232fd9a.; Lagro-Janssen AL, Sluis S. Effectiveness of treating non-specific pruritus vulvae with topical steroids: a randomized controlled trial. Eur J Gen Pract. 2009;15(1):29–33. https://doi.org/10.1080/13814780802705976.; Biro K, Thaçi D, Ochsendorf FR, Kaufmann R, Boehncke WH. Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebocontrolled study. Contact Dermatitis. 2003;49(2):80–84. https://doi.org/10.1111/j.0105-1873.2003.00184.x.; Proksch E, de Bony R, Trapp S, Boudon S. Topical use of dexpanthenol: a 70th anniversary article. J Dermatolog Treat. 2017;28(8):766–773. https://doi.org/10.1080/09546634.2017.1325310.; Мурашкин НН, Материкин АИ, Епишев РВ, Амбарчян ЭТ. Особенности течения и профилактики пеленочного дерматита у новорожденных и детей грудного возраста. Вопросы современной педиатрии. 2015;14(6):710–713. https://doi.org/10.15690/vsp.v14i6.1481.; Peltier E, de Salvo R, Ehret A, Trapp S, Lakomsky D, El Shazly MA. Evaluation of a 5% dexpanthenol-containing ointment for the treatment of infant irritant diaper dermatitis through the lens of the caregiver-A real-world data observational study. Health Sci Rep. 2023;6(1):e1033. https://doi.org/10.1002/hsr2.1033.; Abiko Y, Tomikawa M, Shimizu M. Enzymatic conversion of pantothenylalcohol to pantothenic acid. J Vitaminol. 1969;15(1):59–69. https://doi.org/10.5925/jnsv1954.15.59.; Hrubša M, Siatka T, Nejmanová I, Vopršalová M, Kujovská Krčmová L, Matoušová K et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1 , B2 , B3 , and B5 . Nutrients. 2022;14(3):484. https://doi.org/10.3390/nu14030484.; Williams RJ, Saunders DH. The effects of inositol, crystalline vitamin B(1) and “pantothenic acid” on the growth of different strains of yeast. Biochem J. 1934;28(5):1887–1893. https://doi.org/10.1042/bj0281887.; Ebner F, Heller A, Rippke F, Tausch I. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3(6):427–433. https://doi.org/10.2165/00128071-200203060-0000; Proksch E, Berardesca E, Misery L, Engblom J, Bouwstra J. Dry skin management: practical approach in light of latest research on skin structure and function. J Dermatolog Treat. 2020;31(7):716–722. https://doi.org/10.1080/09546634.2019.1607024.; Stettler H, Kurka P, Lunau N, Manger C, Böhling A, Bielfeldt S et al. A new topical panthenol-containing emollient: Results from two randomized controlled studies assessing its skin moisturization and barrier restoration potential, and the effect on skin microflora. J Dermatolog Treat. 2017;28(2):173–180. https://doi.org/10.1080/09546634.2016.1214235.; Björklund S, Pham QD, Jensen LB, Knudsen NØ, Nielsen LD, Ekelund K et al. The effects of polar excipients transcutol and dexpanthenol on molecular mobility, permeability, and electrical impedance of the skin barrier. J Colloid Interface Sci. 2016;479:207–220. https://doi.org/10.1016/j.jcis.2016.06.054.; Stettler H, Kurka P, Wagner C, Sznurkowska K, Czernicka O, Böhling A, et al. A new topical panthenol-containing emollient: skin-moisturizing effect following single and prolonged usage in healthy adults, and tolerability in healthy infants. J Dermatolog Treat. 2017;28(3):251–257. https://doi.org/10.1080/09546634.2016.1218417.; Udompataikul M, Limpa-o-vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012;11(3):366–374. Available at: https://pubmed.ncbi.nlm.nih.gov/22395588.; Огородова ЛМ, Нагаева ТА, Ходкевич ЛВ. Эффективность декспантенола в комплексном лечении атопического дерматита у детей. Педиатрическая фармакология. 2003;1(3):54–56. Режим доступа: https://cyberleninka.ru/article/n/effektivnost-dekspantenola-v-kompleksnom-lecheniiatopicheskogo-dermatita-u-detey/viewer.; Кубанов АА, Аполихина ИА, Плахова КИ, Чернова НИ, Соколова АВ. Лишай склеротический и атрофический: клинические рекомендации. 2020.; Духанин АС. Водородный показатель (рН) основы топического лекарственного препарата: выбор оптимального значения и роль буферной системы. Клиническая дерматология и венерология. 2016;15(2):47-52. https://doi.org/10.17116/klinderma201615247-52.; Устинов МВ. Эмпирическая терапия воспалительных поражений кожи крупных складок. РМЖ. 2016;(14):945–948. Режим доступа: https://www.rmj.ru/articles/dermatologiya/Empiricheskaya_terapiya_vospalitelynyh_poragheniy_koghi_krupnyh_skladok.; Macura AB. In vitro susceptibility of dermatophytes to antifungal drugs: a comparison of two methods. Int J Dermatol. 1993;32(7):533–536. https://doi.org/10.1111/j.1365-4362.1993.tb02844.x.; Arévalo MP, Carrillo-Muñoz AJ, Salgado J, Cardenes D, Brió S, Quindós G, Espinel-Ingroff A. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother. 2003;51(1):163–166. https://doi.org/10.1093/jac/dkg018.

Availability: https://www.med-sovet.pro/jour/article/view/9024
https://doi.org/10.21518/ms2025-146

Recognizing secondary infection in patients with atopic dermatitis: Head & neck atopic dermatitis ; Распознавание вторичной инфекции у пациентов с атопическим дерматитом лица и шеи (head and neck)

Authors: O. B. Tamrazova, A. V. Tamrazova, G. A. Novik, M. V. Zhdanova, A. S. Stadnikova, A. G. Sukhotina, О. Б. Тамразова, А. В. Тамразова, Г. А. Новик, М. В. Жданова, А. С. Стадникова, А. Г. Сухотина

Contributors: The article was published with support from Bayer, Статья опубликована при поддержке компании «Байер»

Source: Meditsinskiy sovet = Medical Council; № 2 (2025); 42-48 ; Медицинский Совет; № 2 (2025); 42-48 ; 2658-5790 ; 2079-701X

Subject Terms: дупилумаб, head and neck dermatitis, Malassezia spp, glucocorticosteroids, dupilumab, дерматит головы и шеи, глюкокортикостероиды

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8947/7776; Schuler CF, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2023;151(5):1145–1154. https://doi.org/10.1016/j.jaci.2022.10.023.; Eichenfield LF, Stripling S, Fung S, Cha A, O’Brien A, Schachner LA. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. Paediatr Drugs. 2022;24(4):293–305. https://doi.org/10.1007/s40272-022-00499-x.; Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;(92):44–47.; Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126(1):3–12. https://doi.org/10.1016/j.anai.2020.08.002.; Chong AC, Navarro-Triviño FJ, Su M, Park CO. Fungal Head and Neck Dermatitis: Current Understanding and Management. Clin Rev Allergy Immunol. 2024;66(3):363–375. https://doi.org/10.1007/s12016-024-09000-7.; Clemmensen O, Hjorth N. Treatment of dermatitis of the head and neck with ketoconazole in patients with type I sensitivity to Pityrosporum orbiculare. Semin Dermatol. 1983;2:26–29.; Saunders CW, Scheynius A, Heitman J. Malassezia fungi are specialized to live on skin and associated with dandruff, eczema, and other skin diseases. PLoS Pathog. 2012;8(6):e1002701. https://doi.org/10.1371/journal.ppat.1002701.; Glatz M, Bosshard PP, Hoetzenecker W, Schmid-Grendelmeier P. The Role of Malassezia spp. in Atopic Dermatitis. J Clin Med. 2015;4(6):1217–1228. https://doi.org/10.3390/jcm4061217.; Rhimi W, Theelen B, Boekhout T, Otranto D, Cafarchia C. Malassezia spp. Yeasts of Emerging Concern in Fungemia. Front Cell Infect Microbiol. 2020;10:370. https://doi.org/10.3389/fcimb.2020.00370.; Gao Z, Perez-Perez GI, Chen Y, Blaser MJ. Quantitation of major human cutaneous bacterial and fungal populations. J Clin Microbiol. 2010;48(10):3575–3581. https://doi.org/10.1128/JCM.00597-10.; Kaga M, Sugita T, Nishikawa A, Wada Y, Hiruma M, Ikeda S. Molecular analysis of the cutaneous Malassezia microbiota from the skin of patients with atopic dermatitis of different severities. Mycoses. 2011;54(4):e24–e28. https://doi.org/10.1111/j.1439-0507.2009.01821.x.; Szczepańska M, Blicharz L, Nowaczyk J, Makowska K, Goldust M, Waśkiel-Burnat A et al. The Role of the Cutaneous Mycobiome in Atopic Dermatitis. J Fungi (Basel). 2022;8(11):1153. https://doi.org/10.3390/jof8111153.; Buentke E, Scheynius A. Dendritic cells and fungi. APMIS. 2003;111(7-8):789–796. https://doi.org/10.1034/j.1600-0463.2003.11107810.x.; Gehrmann U, Qazi KR, Johansson C, Hultenby K, Karlsson M, Lundeberg L et al. Nanovesicles from Malassezia sympodialis and host exosomes induce cytokine responses – novel mechanisms for host-microbe interactions in atopic eczema. PLoS ONE. 2011;6(7):e21480. https://doi.org/10.1371/journal.pone.0021480.; David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017;1027:21–37. https://doi.org/10.1007/978-3-319-64804-0_3.; Lee YJ, Yassa C, Park SH, Song SW, Jung WH, Lee YW et al. Interactions between Malassezia and New Therapeutic Agents in Atopic Dermatitis Affecting Skin Barrier and Inflammation in Recombinant Human Epidermis Model. Int J Mol Sci. 2023;24(7):6171. https://doi.org/10.3390/ijms24076171.; See Tow HX, Yew YW. Malassezia specific IgE in head and neck dermatitis of eczema: A systematic review & meta-analysis. Exp Dermatol. 2024;33(6):e15108. https://doi.org/10.1111/exd.15108.; Devos SA, van der Valk PG. The relevance of skin prick tests for Pityrosporum ovale in patients with head and neck dermatitis. Allergy. 2000;55(11):1056–1058. https://doi.org/10.1034/j.1398-9995.2000.00782.x.; Danby SG, Cork MJ. pH in Atopic Dermatitis. Curr Probl Dermatol. 2018;54:95–107. https://doi.org/10.1159/000489523.; Selander C, Zargari A, Möllby R, Rasool O, Scheynius A. Higher pH level, corresponding to that on the skin of patients with atopic eczema, stimulates the release of Malassezia sympodialis allergens. Allergy. 2006;61(8):1002–1008. https://doi.org/10.1111/j.1398-9995.2006.01108.x.; Vilhelmsson M, Johansson C, Jacobsson-Ekman G, Crameri R, Zargari A, Scheynius A. The Malassezia sympodialis allergen Mala s 11 induces human dendritic cell maturation, in contrast to its human homologue manganese superoxide dismutase. Int Arch Allergy Immunol. 2007;143(2):155–162. https://doi.org/10.1159/000099082.; Balaji H, Heratizadeh A, Wichmann K, Niebuhr M, Crameri R, Scheynius A, Werfel T. Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. J Allergy Clin Immunol. 2011;128(1):92–99. https://doi.org/10.1016/j.jaci.2011.02.043.; Sparber F, De Gregorio C, Steckholzer S, Ferreira FM, Dolowschiak T, Ruchti F et al. The Skin Commensal Yeast Malassezia Triggers a Type 17 Response that Coordinates Anti-fungal Immunity and Exacerbates Skin Inflammation. Cell Host Microbe. 2019;25(3):389–403. https://doi.org/10.1016/j.chom.2019.02.002.; Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine JP, Pilz M et al. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nat Commun. 2024;15(1):2839. https://doi.org/10.1038/s41467-024-46540-0.; Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fournié P, Simon M. Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. Clin Rev Allergy Immunol. 2022;62(3):519–533. https://doi.org/10.1007/s12016-022-08934-0.; de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745–749. https://doi.org/10.1111/bjd.18730.; Navarro-Triviño FJ, Ayén-Rodríguez Á. Study of Hypersensitivity to Malassezia furfur in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients? Life. 2022;12(2):299. https://doi.org/10.3390/life12020299.; Schlösser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48(5):510–517. https://doi.org/10.1093/ced/llad038.; Mayser P, Kupfer J, Nemetz D, Schäfer U, Nilles M, Hort W, Gieler U. Treatment of head and neck dermatitis with ciclopiroxolamine cream – results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2006;19(3):153–158. https://doi.org/10.1159/000092596.; Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy. 2001;56(6):512–517. https://doi.org/10.1034/j.1398-9995.2001.056006512.x.; Svejgaard El, Larsen PØ, Deleuran M, Ternowitz T, Roed-Petersen J, Nilsson J. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol. 2004;18(4):445–449. https://doi.org/10.1111/j.1468-3083.2004.00963.x.; Kozera E, Flora A, Stewart T, Gill K, Xu J, De La Vega MA, Frew JW. Dupilumab-associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia-specific immunoglobulin E levels mirroring clinical response. J Am Acad Dermatol. 2023;88(1):255–257. https://doi.org/10.1016/j.jaad.2022.05.021.; Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment of atopic dermatitis. J Dermatolog Treat. 2022;33(5):2404–2413. https://doi.org/10.1080/09546634.2021.1967268.; Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L et al. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies. Am J Clin Dermatol. 2024;25(4):669–683. https://doi.org/10.1007/s40257-024-00855-2.

Availability: https://www.med-sovet.pro/jour/article/view/8947
https://doi.org/10.21518/ms2025-055

External therapy of scalp psoriasis: From relieving exacerbations to persistent remission ; Наружная терапия псориаза волосистой части головы: от купирования обострений к стойкой ремиссии

Authors: M. M. Tlish, T. G. Kuznetsova, M. E. Shavilova, F. A. Psavok, М. М. Тлиш, Т. Г. Кузнецова, М. Е. Шавилова, Ф. А. Псавок

Source: Meditsinskiy sovet = Medical Council; № 2 (2025); 91-96 ; Медицинский Совет; № 2 (2025); 91-96 ; 2658-5790 ; 2079-701X

Subject Terms: наружная терапия, topical glucocorticosteroids, betamethasone dipropionate, external therapy, топические глюкокортикостероиды, бетаметазона дипропионат

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8953/7782; Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: a literature review of effective therapies and updated recommendations for practical management. Dermatol Ther. 2021;11(3):769–797. https://doi.org/10.1007/s13555-021-00521-z.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/234_2.; Sriramoju S, Dunde S, Eggadi V, Koppolu MS, Seshagiri SBB. Evaluation of depression and quality of life in patients with psoriasis. Int J Dermatol Venereol. 2022;5(1):27–31. https://doi.org/10.1097/JD9.0000000000000180.; Vičić M, Kaštelan M, Brajac I, Sotošek V, Massari LP. Current concepts of psoriasis immunopathogenesis. Int J Mol Sci. 2021;22(21):11574. https://doi.org/10.3390/ijms222111574.; Suzuki T, Ito T, Gilhar A, Tokura Y, Reich K, Paus R. The hair follicle-psoriasis axis: shared regulatory mechanisms and therapeutic targets. Exp Dermatol. 2022;31(3):266–279. https://doi.org/10.1111/exd.14462.; Polak-Witka K, Rudnicka L, Blume-Peytavi U, Vogt A. The role of the microbiome in scalp hair follicle biology and disease. Exp Dermatol. 2020;29(3):286–294. https://doi.org/10.1111/exd.13935.; Shah RR, Larrondo J, Dawson T, Mcmichael A. Scalp microbiome: a guide to better understanding scalp diseases and treatments. Arch Dermatol Res. 2024;316(8):495. https://doi.org/10.1007/s00403-024-03235-2.; Butacu AI, Toma C, Negulet IE, Manole I, Banica AN, Please A et al. Updates on psoriasis in special areas. J Clin Med. 2024;13(24):7549. https://doi.org/10.3390/jcm13247549.; Huang S, Bai Y. Knowledge mapping and research hotspots of comorbidities in psoriasis: a bibliometric analysis from 2004 to 2022. Medicina. 2023;59(2):393. https://doi.org/10.3390/medicina59020393.; Тлиш ММ, Кузнецова ТГ, Шавилова МЕ, Сычева НЛ, Псавок ФА. Коморбидность у больных хроническими вирусными инфекциями: особенности течения дерматологической патологии. Лечащий врач. 2018;(11):49–53. Режим доступа: https://www.lvrach.ru/2018/11/15437131.; Тлиш ММ, Кузнецова ТГ, Наатыж ЖЮ, Сычева НЛ, Шавилова МЕ, Гаврилова НВ и др. Совершенствование методов диагностики и лечения хронических дерматозов аутоиммунного генеза. Краснодар: Кубанский государственный медицинский университет; 2022. 236 с.; Svedbom A, Mallbris L, Larsson P, Nikamo P, Wolk K, Kjellman P et al. Longterm outcomes and prognosis in new-onset psoriasis. JAMA Dermatol. 2021;157(6):684–690. https://doi.org/10.1001/jamadermatol.2021.0734.; Тлиш ММ, Шавилова МЕ. Контактный дерматит: этиопатогенетические аспекты формирования клинической картины и рациональный выбор наружной терапии. Медицинский совет. 2023;(14):37–42. https://doi.org/10.21518/ms2023-263.; Тлиш ММ, Шавилова МЕ, Сычева НЛ, Псавок ФА. Топические глюкокортикостероиды: от высокой клинической эффективности к проблеме бесконтрольного применения (обзор клинических случаев). Медицинский совет. 2023;(6):186–192. https://doi.org/10.21518/ms2023-043.; Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(3):36–46. https://doi.org/10.1111/j.1468-3083.2012.04522.x.; Белоусова ТА, Каиль МВ. Терапевтические возможности наружных глюкокортикостероидов в современной клинической практике. Медицинский совет. 2020;(12):36–45. https://doi.org/10.21518/2079-701X2020-12-36-45.

Availability: https://www.med-sovet.pro/jour/article/view/8953
https://doi.org/10.21518/ms2025-068

The effectiveness of using a combination of glucocorticosteroid and salicylic acid in the form of a solution for psoriasis vulgaris of the scalp ; Возможности применения комбинации глюкокортикостероида и салициловой кислоты в форме раствора при псориазе вульгарном

Authors: A. A. Arsenyeva, E. V. Orlov, J. M. Pakhomova, А. А. Арсеньева, Е. В. Орлов, Ю. М. Пахомова

Source: Meditsinskiy sovet = Medical Council; № 23 (2024); 199-204 ; Медицинский Совет; № 23 (2024); 199-204 ; 2658-5790 ; 2079-701X

Subject Terms: Акридерм СК, betamethasone, psoriasis, scalp psoriasis, glucocorticosteroids, solution, Akriderm SK, бетаметазон, псориаз, псориаз волосистой части головы, глюкокортикостероиды, раствор

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8847/7755; Матушевская ЕВ, Коновалова МВ, Владимирова ЕВ, Свирщевская ЕВ. Патогенез и терапия псориаза и псориатического артрита. Клиническая дерматология и венерология. 2019;18(5):626–634. https://doi.org/10.17116/klinderma201918051626.; Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265. https://doi.org/10.1016/j.jaad.2018.06.027.; Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32. https://doi.org/10.1002/art.40726.; Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R et al. Longterm safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–285. https://doi.org/10.1016/j.jaad.2018.09.002.; Кубанов АА, Карамова АЭ, Притуло ОА, Аршинский МИ, Знаменская ЛФ, Чикин ВВ и др. Псориаз: клинические рекомендации. М.; 2023. Режим доступа: https://cr.minzdrav.gov.ru/recomend/234_2.; Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. https://doi.org/10.1001/jama.2020.4006.; Benhadou F, Mintoff D, Del Marmol V. Psoriasis: Keratinocytes or Immune Cells – Which Is the Trigger? Dermatology. 2019;235(2):91–100. https://doi.org/10.1159/000495291.; Stewart CR, Algu L, Kamran R, Leveille CF, Abid K, Rae C, Lipner SR. The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review. Skin Appendage Disord. 2021;7(2):83–89. https://doi.org/10.1159/000512688.; Meneguin S, de Godoy NA, Pollo CF, Miot HA, de Oliveira C. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatol. 2020;20(1):22. https://doi.org/10.1186/s12895-020-00116-9.; Egeberg А, See К, Garrelts А, Burge R. Epidemiology of psoriasis in hardtotreat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. https://doi.org/10.1186/s12895-020-00099-7.; Nakamura M, Koo J. Safety considerations with combination therapies for psoriasis. Expert Opin Drug Saf. 2020;19(4):489–498. https://doi.org/10.1080/14740338.2020.1722640.; Bernardini N, Skroza N, Tolino E, Marchesiello A, Mambrin A, Balduzzi V et al. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study. Clin Ter. 2020;171(4): e310–e315. https://doi.org/10.7417/CT.2020.2234.; Hadeler E, Mosca M, Hong J, Brownstone N, Bhutani T, Liao W. Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatol Ther. 2021;11(3):799–831. https://doi.org/10.1007/s13555-021-00523-x.; Rigopoulos D, Rompoti N, Gregoriou S. Management of Nail Psoriasis. Dermatol Clin. 2021;39(2):211–220. https://doi.org/10.1016/j.det.2020.12.014.; Платонова АВ, Жуков АС, Хайрутдинов ВР, Самцов АВ. Псориатическая ониходистрофия: индексы оценки степени тяжести (часть 2). Вестник дерматологии и венерологии. 2019;95(1):9–14. https://doi.org/10.25208/0042-4609-2019-95-1-9-14.

Availability: https://www.med-sovet.pro/jour/article/view/8847
https://doi.org/10.21518/ms2024-434

Modern view on the problem of therapy of recurrent polyposis rhinosinusitis, comparative study of the effectiveness of different monoclonal antibody preparations ; Современный взгляд на проблему терапии рецидивирующего полипозного риносинусита: сравнительное исследование эффективности применения различных препаратов моноклональных антител

Authors: A. I. Kryukov, A. V. Gurov, D. S. Fomina, A. S. Tovmasyan, G. K. Rabadanov, А. И. Крюков, А. В. Гуров, Д. С. Фомина, А. С. Товмасян, Г. К. Рабаданов

Source: Meditsinskiy sovet = Medical Council; № 23 (2024); 80-86 ; Медицинский Совет; № 23 (2024); 80-86 ; 2658-5790 ; 2079-701X

Subject Terms: биологическая терапия, bronchial asthma, inhaled glucocorticosteroids, chronic polyposis rhinosinusitis, biological therapy, бронхиальная астма, ингаляционные глюкокортикостероиды, хронический полипозный риносинусит

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8830/7739; Larsen K, Tos M. Clinical course of patients with primary nasal polyps. Acta Otolaryngol. 1994;114(5):556–559. https://doi.org/10.3109/00016489409126104.; Slater A, Smallman LA, Logan AC, Drake-Lee AB. Mucociliary function in patients with nasal polyps. Clin Otolaryngol Allied Sci. 1996;21(4):343–347. https://doi.org/10.1111/j.1365-2273.1996.tb01084.x.; Носуля ЕВ, Ким ИА, Афанасьева НВ, Сумбаева ОВ. Распространенность полипозного риносинусита среди городского населения Восточной Сибири. Российская ринология. 2007;(1):4–8. Режим доступа: https://elibrary.ru/hzqvaz.; Арефьева НА, Вишняков ВВ, Вахрушев СГ. Полипозный риносинусит. Клинические рекомендации. М.; 2010.; Пискунов ГЗ. Клинические фенотипы полипозного риносинусита. Российская ринология. 2019;27(4):224–231. https://doi.org/10.17116/rosrino201927041224.; Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Am J Respir Crit Care Med. 2022;205(1):17–35. https://doi.org/10.1164/rccm.202109-2205PP.; Chuchalin AG, Khaltaev N, Antonov NS, Galkin DV, Manakov LG, Antonini P et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. https://doi.org/10.2147/copd.s67283.; Геппе НА, Колосова НГ. Национальная программа «Бронхиальная астма у детей», 2012. Стратегия лечения. Consilium Medicum. Пульмонология (Прил.). 2012;(1):39–41. Режим доступа: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/consilium-medicum/cm2012/pulmo_2012_pril/natsionalnaya-programma-bronkhialnaya-astma-u-detey-2012-strategiya-lecheniya.; Samoliński B, Szczesnowicz-Dabrowska P. Relationship between inflammation of upper and lower respiratory airways. Otolaryngol Pol. 2002;56(1):49–55. Available at: https://pubmed.ncbi.nlm.nih.gov/12053668/.; Serrano E, Neukirch F, Pribil C, Jankowski R, Klossek JM, Chanal I, El Hasnaoui A. Nasal polyposis in France: Impact on sleep and quality of life. J Laringol Otol. 2005;119(7):543–549. https://doi.org/10.1258/0022215054352108.; Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24(5):758–764. https://doi.org/10.1183/09031936.04.00013904.; Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006;61(6):693–698. https://doi.org/10.1111/j.1398-9995.2006.01054.x.; Nathan RA, O Meltzer E, Derebery J, Campbell UB, Stang PE, Corrao MA et al. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc. 2008;29(6):600–608. https://doi.org/10.2500/aap.2008.29.3179.; Katelaris CH, Lee BW, Potter PC, Maspero JF, Cingi C, Lopatin A et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012;42(2):186–207. https://doi.org/10.1111/j.1365-2222.2011.03891.x.; Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW et al. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy. 2015;13(1):1. https://doi.org/10.1186/s12948-015-0008-x.; Cingi C, Yorgancioglu A, Cingi CC, Oguzulgen K, Muluk NB, Ulusoy S et al. The “physician on call patient engagement trial” (POPET): measuring the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis and asthma patients. Int Forum Allergy Rhinol. 2015;5(6):487–497. https://doi.org/10.1002/alr.21468.; Xiao J, Wu WX, Ye YY, Lin WJ, Wang L. A network meta-analysis of randomized controlled trials focusing on different allergic rhinitis medications. Am J Ther. 2016;23(6):e1568-e1578. https://doi.org/10.1097/mjt.0000000000000242.; Савлевич ЕЛ, Гаганов ЛЕ, Егоров ВИ, Курбачева ОМ, Герасимов АН, Шачнев КН. Сравнительное пилотное исследование эндотипов хронического полипозного риносинусита у пациентов, проживающих в разных географических регионах Российской Федерации. Иммунология. 2018;39(4):208–213. Режим доступа: https://cyberleninka.ru/article/n/sravnitelnoe-pilotnoe-issledovanie-endotipov-hronicheskogo-polipoznogorinosinusita-u-patsientov-prozhivayuschih-v-raznyh/viewer.; Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–1456.e4. https://doi.org/10.1016/j.jaci.2015.12.1324.; Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/rhin20.600.; Lund VJ, Kennedy DW. Quantification for staging sinusitis. Ann Otol Rhinol Laryngol Suppl. 1995;167:17–21. Available at: https://pubmed.ncbi.nlm.nih.gov/7574265/.; Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. https://doi.org/10.1056/nejmoa1403290.; Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511. https://doi.org/10.1016/j.anai.2018.01.030.; Козлов ВС, Савлевич ЕЛ. Полипозный риносинусит. Современные подходы к изучению патогенеза, диагностике и лечению. Вестник оториноларингологии. 2015;80(4):95–99. https://doi.org/10.17116/otorino201580495-99.; Рязанцев СВ, Будковая МА. Тактика лечения полипозного риносинусита. Российская оториноларингология. 2017;(2):162–169. https://doi.org/10.18692/1810-4800-2017-2-162-169.; Лопатин АС. Современные теории патогенеза полипозного риносинусита. Пульмонология. 2003;(5):110–115. Режим доступа: https://journal.pulmonology.ru/pulm/article/view/2629/2061.; Пискунов ГЗ. Физиологическое и патофизиологическое обоснование функциональной риносинусохирургии. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018;24(1):23–28. Режим доступа: https://www.elibrary.ru/yulkqc.; Курбачева ОМ, Дынева МЕ, Ильина НИ. Дупилумаб: основные аспекты применения при T2-опосредованных заболеваниях. Медицинский cовет. 2021;(16):186–196. https://doi.org/10.21518/2079-701X-2021-16-186-196.; Hopkins C. Ethical dilemmas associated with the introduction of biologic treatments in chronic rhinosinusitis with nasal polyps. Rhinology. 2022;60(3):162–168. https://doi.org/10.4193/Rhin21.477.; Karin J, Tim D, Gabriele H, Cardell LO, Marit W, Claus B. Type 2 inflammatory shift in chronic rhinosinusitis during 2007–2018 in Belgium. Laryngoscope. 2021;131(5):E1408–E1414. https://doi.org/10.1002/lary.29128.; Аллахверанов ДАО, Юнусов АС, Рябинин АГ. Отдаленные результаты эндоскопических методов лечения хронического полипозного риносинусита. Российская оториноларингология. 2015;(3):158–160. Режим доступа: https://cyberleninka.ru/article/n/otdalennye-rezultaty-endoskopicheskihmetodov-lecheniya-hronicheskogo-polipoznogo-rinosinusita.; Завадский АВ, Завадский НВ, Золотарева МА. Ведение послеоперационного периода у больных полипозом носа. Российская оториноларингология. 2015;(5):89–94. Режим доступа: https://www.elibrary.ru/unldtd.; Широкая АВ, Свистушкин ВМ, Шатохина СН, Шабалин ВН. Оценка эффективности лечения больных полипозным риносинуситом и прогноз его течения. Российская оториноларингология. 2013;(2):96–104. Режим доступа: https://cyberleninka.ru/article/n/otsenka-effektivnosti-lecheniyabolnyh-polipoznym-rinosinusitom-i-prognoz-ego-techeniya.; Campbell RG. Risks and management of long-term corticosteroid use in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2018;26(1):1–7. https://doi.org/10.1097/moo.0000000000000421.; Han J, Gross G, Mannent L, Amin N, Cho S, Bachert C. Dupilumab Improves Sinus Opacification in All Sinuses in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Results From the SINUS-24 Phase 3 Study. J Allergy Clin Immunol. 2020;145(2):AB251. https://doi.org/10.1016/j.jaci.2019.12.109.; Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312–2319. https://doi.org/10.1111/all.13875.; Al-Ahmad M, Alsaleh S, Al-Reefy H, Abduwani JA, Nasr I, Al Abri R et al. Expert opinion on biological treatment of chronic rhinosinusitis with nasal polyps in the gulf region. J Asthma Allergy. 2022;15:1–12. https://doi.org/10.2147/jaa.s321017.

Availability: https://www.med-sovet.pro/jour/article/view/8830
https://doi.org/10.21518/ms2024-510

CLINICAL FEATURES OF GASTROINTESTINAL TRACT LESIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ; КЛИНИЧЕСКИЕ ОСОБЕННОСТИ ПОРАЖЕНИЯ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТА У ПАЦИЕНТОВ С СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКОЙ ; TIZIMLI QIZIL YUGURUK BILАN OGʼRIGАN BEMORLАRDА OSHQOZON-ICHАK TRАKTI ZARARLANISHINING KLINIK XUSUSIYATLАRI

Authors: Iskanova, Gulshan, Egamova, Sayyora, Israilova, Nigora

Source: Medical science of Uzbekistan; No. 2 (2025): March-April; 32-34 ; Медицинская наука Узбекистана; № 2 (2025): Март-Апрель; 32-34 ; O`zbekiston tibbiyot ilmi; No. 2 (2025): Mart-Aprel; 32-34 ; 2181-3612

Subject Terms: Systemic lupus erythematosus, glucocorticosteroids, gastrointestinal pathology, Системная красная волчанка, глюкокортикостероиды, гастроинтестинальная патология, tizimli qizil yuguruk, glyukokortikosteroidlar, oshqozon-ichak patologiyasi

File Description: application/pdf

Relation: https://fdoctors.uz/index.php/journal/article/view/112/81; https://fdoctors.uz/index.php/journal/article/view/112

Availability: https://fdoctors.uz/index.php/journal/article/view/112
https://doi.org/10.56121/2181-3612-2025-2-32-34

The effects of glucocorticosteroids and their specific usage in athletes. ; EFECTELE GLUCOCORTICOSTEROIZILOR ȘI PARTICULARITĂȚILE LOR DE UTILIZARE LA SPORTIVI ; Эффекты глюкокортикостероидов и их специфическое применение у спортсменов.

Authors: POGONEA, Ina, MIHALACHI-ANGHEL , Maria, TIMERCAN, Tatiana, JUCOV, Artiom, STRATULAT , Silvia, TABIRTA, Alisa, CHIHAI , Victoria, STEFANET, Gheorghe, MEREACRI, Liviu

Source: Bulletin of the Academy of Sciences of Moldova. Medical Sciences; Vol. 79 No. 2 (2024): Medical Sciences; 224-228 ; Buletinul Academiei de Științe a Moldovei. Științe medicale; Vol. 79 Nr. 2 (2024): Ştiinţe medicale; 224-228 ; Вестник Академии Наук Молдовы. Медицина; Том 79 № 2 (2024): Медицина; 224-228 ; 1857-0011

Subject Terms: глюкокортикостероиды, физическая производительность, запрещенные вещества, усталость, эйфория, спортивные правила, Glucocorticosteroizi, performanță fizică, substanțe interzise, oboseală, euforie, reglementări sportive, Glucocorticosteroids, physical performance, prohibited substances, fatigue, euphoria, sports regulations

File Description: application/pdf

Relation: https://bulmed.md/bulmed/article/view/3698/3689; https://bulmed.md/bulmed/article/view/3698

Availability: https://bulmed.md/bulmed/article/view/3698
https://doi.org/10.52692/1857-0011.2024.2-79.42

Efectele glucocorticosteroizilor și particularitățile lor de utilizare la sportive

Authors: Pogonea, I., Mihalachi-Anghel, M., Timercan, T.V., Jucov, A.V., Stratulat, S.P., Tabirta, A., Chihai, V.I., Ştefaneţ, G.M., Mereacri, L.

Source: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale 79 (2) 224-228

Subject Terms: substanţe interzise, euphoria, sports regulations, performanță fizică, глюкокортикостероиды, эйфория, prohibited substances, glucocorticosteroids, physical performance, euforie, физическая производительность, Glucocorticosteroizi, усталость, oboseala, reglementări sportive, спортивные правила, fatigue, запрещенные вещества

File Description: application/pdf

Access URL: https://ibn.idsi.md/vizualizare_articol/218021

ВЛИЯНИЕ СИСТЕМНЫХ ГЛЮКОКОРТИКОСТЕРОИДОВ НА РАЗВИТИЕ АСЕПТИЧЕСКОГО НЕКРОЗА СУСТАВОВ У ПАЦИЕНТОВ С КОРОНАВИРУСНОЙ ИНФЕКЦИЕЙ

Authors: Вахнина К.В., Пятых Е.А., Павлова К.А.

Source: Cifra: Клиническая медицина, Vol 1, Iss 1 (2024)

Subject Terms: коронавирусная инфекция, глюкокортикостероиды, тромбообразование, остеонекроз, асептический некроз головки бедренной кости, coronavirus infection, glucocorticosteroids, thrombosis, osteonecrosis, aseptic necrosis of the femoral head, Medicine

File Description: electronic resource

Relation: https://clinicalmedicine.cifra.science/archive/1-1-2024-july/10.62993/CMED.2024.1.1; https://doaj.org/toc/3034-333X

Access URL: https://doaj.org/article/5cfb49ae124243e1990489abb3a39b13

СОВРЕМЕННЫЕ СПОСОБЫ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ И ИХ КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ

Subject Terms: бронхиальная астма, эффективность лечения, клиническая картина, ингаляционные глюкокортикостероиды, ксантины, дети

СОВРЕМЕННЫЕ СПОСОБЫ ЛЕЧЕНИЯ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ И ИХ КЛИНИКО-ФУНКЦИОНАЛЬНЫЕ ОСОБЕННОСТИ

Subject Terms: бронхиальная астма, эффективность лечения, клиническая картина, ингаляционные глюкокортикостероиды, ксантины, дети

A relation between chronic rhinosinusitis with nasal polyps and COVID-19 course ; Взаимосвязь между хроническим риносинуситом и тяжестью течения COVID-19

Authors: Lyubimova E.V., Savlevich E.L., Zurochka A.V., Mitrofanova Е.S.

Contributors: 1

Source: Russian Journal of Infection and Immunity; Vol 14, No 6 (2024); 1070-1078 ; Инфекция и иммунитет; Vol 14, No 6 (2024); 1070-1078 ; 2313-7398 ; 2220-7619

Subject Terms: chronic rhinosinusitis, chronic rhinosinusitis with nasal polyps, COVID-19, SARS-CoV-2, angiotensin-converting enzyme (ACE)-2, local glucocorticosteroid, systemic glucocorticosteroid, frequency of hospitalization, biological therapy, post-COVID syndrome, хронический риносинусит, полипозный риносинусит, ангиотензинпревращающий фермент (ACE)-2, системные глюкокортикостероиды, топические глюкокортикостероиды, частота госпитализации, биологическая терапия, постковидный синдром

File Description: application/pdf

Relation: https://iimmun.ru/iimm/article/view/16667/2120; https://iimmun.ru/iimm/article/view/16667/2160; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129011; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129012; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129013; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129014; https://iimmun.ru/iimm/article/downloadSuppFile/16667/129015; https://iimmun.ru/iimm/article/view/16667

Availability: https://iimmun.ru/iimm/article/view/16667
https://doi.org/10.15789/2220-7619-ARB-16667

MATERNAL AND PERINATAL OUTCOMES IN PRETERM BIRTH DEPENDING ON THE METHOD OF DELIVERY

Authors: Сергей Владимирович Баринов, Серик Саятович Искаков, Сауле Батыровна Аманбекова, Алексей Николаевич Ятманов, Анна Николаевна Богатырёва

Source: Мать и дитя в Кузбассе, Vol 24, Iss 3, Pp 67-73 (2023)

Subject Terms: преждевременные роды, кесарево сечение, глюкокортикостероиды, безводный период, антибиотики, преэклампсия, преждевременный разрыв плодных оболочек, Pediatrics, RJ1-570, Gynecology and obstetrics, RG1-991

File Description: electronic resource

Relation: https://mednauki.ru/index.php/MD/article/view/920; https://doaj.org/toc/1991-010X; https://doaj.org/toc/2542-0968

Access URL: https://doaj.org/article/34f251b6878a421b95630912c65ec3e2

Сучасні підходи до вибору базисної терапії легкої персистуючої бронхіальної астми у дітей

Authors: Nedelska, S.M., Kuznietsova, O.D., Raskina, K.V.

Source: Zdorovʹe Rebenka, Vol 10, Iss 2.61, Pp 62-65 (2015)
CHILD`S HEALTH; № 2.61 (2015); 62-65
Здоровье ребенка-Zdorovʹe rebenka; № 2.61 (2015); 62-65
Здоров'я дитини-Zdorovʹe rebenka; № 2.61 (2015); 62-65

Subject Terms: children, бронхиальная астма, ингаляционные глюкокортикостероиды, антилейкотриеновые препараты, дети, leukotrien modifiers, бронхіальна астма, інгаляційні глюкокортикостероїди, антилейкотрієнові препарати, діти, bronchial asthma, inhaled glucocorticosteroids, Pediatrics, RJ1-570, 3. Good health

File Description: application/pdf

Access URL: https://doaj.org/article/02742bb584a04587aa62ffb85cbd424d
http://childshealth.zaslavsky.com.ua/article/download/75067/70513
http://childshealth.zaslavsky.com.ua/article/view/75067
http://childshealth.zaslavsky.com.ua/article/view/75067

Review of modern techniques and analysis of patient outcomes with benign familial pemphigus Gougereau–Haley–Haley ; Обзор современных методик и анализ результативности лечения пациентов с доброкачественной хронической семейной пузырчаткой Гужеро–Хейли–Хейли

Authors: Drozhdina M.B., Koshkin S.V.

Source: Vestnik dermatologii i venerologii; Vol 100, No 6 (2024); 70-80 ; Вестник дерматологии и венерологии; Vol 100, No 6 (2024); 70-80 ; 2313-6294 ; 0042-4609 ; 10.25208/vdv.1006

Subject Terms: benign familial pemphigus, glucocorticosteroids, naltrexone, apremilast, botulinum toxin, доброкачественная хроническая семейная пузырчатка Гужеро–Хейли–Хейли, глюкокортикостероиды, налтрексон, апремиласт, ботулотоксин

File Description: application/pdf

Relation: https://vestnikdv.ru/jour/article/view/16783/pdf; https://vestnikdv.ru/jour/article/view/16783/pdf_1; https://vestnikdv.ru/jour/article/view/16783/pdf_2; https://vestnikdv.ru/jour/article/view/16783/pdf_3; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158413; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158415; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158417; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158418; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158432; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158433; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158434; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158435; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158436; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158437; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158458; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158459; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158460; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158461; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158526; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158890; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158891; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158892; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158893; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/158894; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/159161; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/159162; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/159163; https://vestnikdv.ru/jour/article/downloadSuppFile/16783/159164; https://vestnikdv.ru/jour/article/view/16783

Availability: https://vestnikdv.ru/jour/article/view/16783
https://doi.org/10.25208/vdv16783

Results of analysis of the sarcoidosis registry of the Republic of Tatarstan ; Результаты анализа регистра пациентов с саркоидозом Республики Татарстан

Authors: A. A. Vizel, S. N. Avdeev, I. Yu. Vizel, G. R. Shakirova, E. Z. Kudryavtseva, R. I. Shaymuratov, A. V. Tikhonov, A. R. Abashev, L. A. Vizel, А. А. Визель, С. Н. Авдеев, И. Ю. Визель, Г. Р. Шакирова, Э. З. Кудрявцева, Р. И. Шаймуратов, А. В. Тихонов, А. Р. Абашев, Л. А. Визель

Source: PULMONOLOGIYA; Том 34, № 4 (2024); 487-497 ; Пульмонология; Том 34, № 4 (2024); 487-497 ; 2541-9617 ; 0869-0189

Subject Terms: системные глюкокортикостероиды, register, diagnosis, verification, treatment, systemic corticosteroids, регистр, диагностика, верификация, лечение

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4423/3683; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4423/2375; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4423/2391; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4423/2392; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4423/2393; Визель И.Ю., Визель А.А. Характеристика регистра больных саркоидозом в Республике Татарстан. Вестник современной клинической медицины. 2015; 8 (5): 18–26. Доступно на: http://www.vskmjournal.org/ru/vypuski-zhurnala/19-2015-ru/18-tom-8-vypusk-5-2015.html#a18; Визель А.А., Шакирова Г.Р., Визель И.Ю. и др. База данных больных саркоидозом Республики Татарстан: ретроспективный анализ за 50 лет. Альманах клинической медицины. 2020; 48 (5): 291–298. DOI:10.18786/2072-0505-2020-48-055.; Gabriel E.E., Arkema E.V., Sachs M.C. Direct modeling of relative and absolute risks in register data: Mortality risk in sarcoidosis. Ann. Epidemiol. 2022; 66: 1–4. DOI:10.1016/j.annepidem.2021.11.003.; Нашатырева М.С., Трофименко И.Н., Черняк Б.А. Структура и клиническая характеристика интерстициальных заболеваний лёгких по данным регистра (Иркутск). Пульмонология. 2017; 27 (6): 740–747. DOI:10.18093/0869-0189-2017-27-6-740-747.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Саркоидоз: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (6): 806–833. DOI:10.18093/0869-0189-2022-32-6-806-833.; Визель А.А., Визель И.Ю., Шакирова ГР, Визель ЛА. Характеристика пациентов с саркоидозом, обратившихся к пульмонологу в период пандемии COVID-19. Медицинский совет. 2023; 17 (20): 26–33. DOI:10.21518/ms2023-289.; Desbois A.C., Marques C., Lefèvre L. et al. Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. Clin. Exp. Rheumatol. 2022; 40 (1): 195–196. DOI:10.55563/clinexprheumatol/b7zd6b.; Khan M.A., Ibad H.A., Hamid Hussain S.M. et al. Sarcoidosis: An experience from a tertiary care center in Karachi Pakistan. J. Pak. Med. Assoc. 2022; 72 (4): 785–789. DOI:10.47391/JPMA.0411.; Thillai M., Chang W., Chaudhuri N. et al. Sarcoidosis in the UK: insights from British Thoracic Society registry data. BMJ Open Respir. Res. 2019; 6 (1): e000357. DOI:10.1136/bmjresp-2018-000357.; Masumoto N., Watanabe K., Horita N. et al. Elderly sarcoidosis in Japan. J. Int. Med. Res. 2022; 50 (12): 3000605221142705. DOI:10.1177/03000605221142705.; Сперанская А.А., Баранова О.П., Кудряшова Т.Г., Ярцева Е.Э. Клинико лучевые особенности саркоидоза органов дыхания у лиц молодого возраста. Визуализация в медицине. 2022; 4 (1): 16–25. Доступно на: https://ojs3.gpmu.org/index.php/visual-med/article/view/4091; Konak H.E., Güven S.C., Atalar E. et al. A single-center rheumatology experience of sarcoidosis: observations from 70 patients. Sarcoidosis Vasc. Diffuse Lung Dis. 2023; 40 (3): e2023033. DOI:10.36141/svdld.v40i3.14063.; Park J.E., Kim Y.S., Kang M.J. et al. Prevalence, incidence, and mortality of sarcoidosis in Korea, 2003-2015: a nationwide population-based study. Respir. Med. 2018; 144S: S28–34. DOI:10.1016/j.rmed.2018.03.028.; Seedahmed M.I., Baugh A.D., Albirair M.T. et al. Epidemiology of sarcoidosis in U.S. veterans from 2003 to 2019. Ann. Am. Thorac. Soc. 2023; 20 (6): 797–806. DOI:10.1513/AnnalsATS.202206-515OC.; Смирнова М.С., Бережонова М.С. Стандартизация медицинской помощи пациентам с саркоидозом. Проблемы стандартизации в здравоохранении. 2018; (1-2): 14–24. DOI:10.26347/1607-2502201801-02014-019.; Gade Sikjær M., Hilberg O., Ibsen R. et al. Direct and indirect economic and health consequences related to sarcoidosis in Denmark: a national register-based study. Respir. Med. 2019; 152: 7–13. DOI:10.1016/j.rmed.2019.04.004.; Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan. Eur. Respir. J. 2008; 31 (2): 372–379. DOI:10.1183/09031936.00075307.; Haraldsdóttir S.Ó., Jonasson J.G., Jorundsdottir K.B. et al. Sarcoidosis in Iceland: a nationwide study of epidemiology, clinical picture and environmental exposure. ERJ Open Res. 2021; 7 (4): 00550-2021. DOI:10.1183/23120541.00550-2021.; https://journal.pulmonology.ru/pulm/article/view/4423

Availability: https://journal.pulmonology.ru/pulm/article/view/4423
https://doi.org/10.18093/0869-0189-2024-34-4-487-497

Prospects for adjuvant therapy with systemic corticosteroids for community-acquired pneumonia: from experiment to clinical practice ; Перспективы адъювантной терапии внебольничной пневмонии системными глюкокортикостероидами: от эксперимента к клинической практике

Authors: Yu. V. Rudakov, V. V. Salukhov, M. A. Kharitonov, N. I. Voloshin, S. N. Avdeev, Ю. В. Рудаков, В. В. Салухов, М. А. Харитонов, Н. И. Волошин, С. Н. Авдеев

Contributors: The study was not sponsored, Авторы декларируют отсутствие внешнего финансирования для публикации статьи

Source: PULMONOLOGIYA; Том 34, № 6 (2024); 775-787 ; Пульмонология; Том 34, № 6 (2024); 775-787 ; 2541-9617 ; 0869-0189

Subject Terms: острое повреждение легких, community-acquired pneumonia, adjuvant therapy, acute lung injury, глюкокортикостероиды, внебольничная пневмония, адъювантная терапия

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4662/3712; Cillóniz C., Cardozo C., García-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. Ann. Res. Hosp. 2018; (2): 1. DOI:10.21037/arh.2017.12.03.; Авдеев С.Н., Белобородов В.Б., Белоцерковский Б.З. и др. Тяжелая внебольничная пневмония у взрослых. Клинические рекомендации Федерации анестезиологов и реаниматологов России. Анестезиология и реаниматология. 2022; (1): 6–35. DOI:10.17116/anaesthesiology20220116.; Минаков А.А., Вахлевский В.В., Волошин Н.И. и др. Новый взгляд на этиологию и иммунологические аспекты пневмонии. Медицинский совет. 2023; 17 (4): 141–153. DOI:10.21518/ms2023-056.; Ruiz-Spinelli A., Waterer G., Rello J. Severe community-acquired pneumonia in the post COVID-19 era. Curr. Opin Crit. Care. 2023; 29 (5): 400–406. DOI:10.1097/MCC.0000000000001083.; Battaglini D., Fazzini B., Silva P.L. et. al. Challenges in ARDS definition, management, and identification of effective personalized therapies. Clin. Med. 2023; 12 (4): 1381. DOI:10.3390/jcm12041381.; Buttgereit F., da Silva J.A., Boers M. et. al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann. Rheum. Dis. 2002; 61 (8): 718–722. DOI:10.1136/ard.61.8.718.; Pastores S.M., Annane D., Rochwerg B. et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically Ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit. Care Med. 2018; 46 (1): 146–148. DOI:10.1097/CCM.0000000000002737.; Czock D., Keller F., Rasche F.M. et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005. 44 (1): 61–98. DOI:10.2165/00003088-200544010-00003.; Williams D.M. Clinical pharmacology of corticosteroids. Respir. Care. 2018; 63 (6): 655–670. DOI:10.4187/respcare.06314.; Yang J.W., Mao B., Tao R.J. Corticosteroids alleviate lipopolysaccharide-induced inflammation and lung injury via inhibiting NLRP3-inflammasome activation. J. Cell. Mol. Med. 2020; 24 (21): 12716–12725. DOI:10.1111/jcmm.15849.; Tu G.W., Shi Y., Zheng Y.J. et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. J. Transl. Med. 2017; 15 (1): 181. DOI:10.1186/s12967-017-1284-7.; Волошин Н.И., Пугач В.А., Салухов В.В. и др. Экспериментальное исследование эффективности дексаметазона на модели липополисахарид-индуцированного острого повреждения легких у крыс. Бюллетень сибирской медицины. 2023; 22 (4): 22–30. DOI:10.20538/1682-0363-2023-4-22-30.; Venkatesh B., Finfer S., Cohen J. et al. Adjunctive glucocorticoid therapy in patients with septic shock. N. Engl. J. Med. 2018; 378 (9): 797–808. DOI:10.1056/NEJMoa1705835.; Kamath S., Hammad Altaq H., Abdo T. Management of sepsis and septic shock: what have we learned in the last two decades? Microorganisms. 2023; 11 (9): 2231. DOI:10.3390/microorganisms11092231.; Lewis S.R., Pritchard M.W., Thomas C.M. et al. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst. Rev. 2019; 7 (7): CD004477. DOI:10.1002/14651858.cd004477.pub3.; Lin P., Zhao Y., Li X. et al. Decreased mortality in acute respiratory distress syndrome patients treated with corticosteroids: an updated meta-analysis of randomized clinical trials with trial sequential analysis. Crit. Care. 2021; 25 (1): 122. DOI:10.1186/s13054-021-03546-0.; Yoshihro S., Taito S., Yatabe T. The influence of steroid type on outcomes in patients with acute respiratory distress syndrome. J. Intensive Care. 2023; 11 (1): 32. DOI:10.1186/s40560-023-00681-4.; He Q., Wang C., Wang Y. et al. Efficacy and safety of glucocorticoids use in patients with COVID-19: a systematic review and network meta-analysis. BMC Infect. Dis. 2023; 23 (1): 896. DOI:10.1186/s12879-023-08874-w.; Saleem N., Kulkarni A., Snow T.A.C. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials. Chest. 2023; 163 (3): 484–497. DOI:10.1016/j.chest.2022.08.2229.; Tang Q., Chen Q., Li Y., Wang Z. Association between glucocorticoids and mortality in patients with severe pneumonia: a systematic review and meta-analysis based on randomized controlled trials. Comput. Math. Methods Med. 2022; 2022: 1191205. DOI:10.1155/2022/1191205.; Chen S., Hu C. Effect of corticosteroids on mortality in patients with community-acquired pneumonia. Crit. Care. 2023; 27 (1): 358. DOI:10.1186/s13054-023-04645-w.; Wu J.Y., Tsai Y.W., Hsu W.H. et al. Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit. Care. 2023; 27 (1): 274. DOI:10.1186/s13054-023-04561-z.; Bradley J., Khurana S., Cavallazzi R. Adjunctive immunomodulation in severe community-acquired pneumonia. J. Bras. Pneumol. 2023; 49 (4): e20230248. DOI:10.36416/1806-3756/e20230248.; Martin-Loeches I., Nagavci B., Torres A. Final approval for corticosteroids in severe CAP? For sure, in septic shock. Crit. Care. 2023; 27 (1): 342. DOI:10.1186/s13054-023-04613-4.; Amratia D.A., Viola H., Ioachimescu O.C. Glucocorticoid therapy in respiratory illness: bench to bedside. J. Investig Med. 2022; 70 (8): 1662–1680. DOI:10.1136/jim-2021-002161.; Vornicu O., Perriens E., Blackman S. et. al. Mortality reduction in severe community-acquired pneumonia: key findings from a large randomized controlled trial and their clinical implications. Ann. Transl. Med 2023; 11 (11): 395. DOI:10.21037/atm-23-1719.; Abdallah M.S., Madi A.F., Rana M.A. The best use of systemic corticosteroids in the intensive care units, review. J. Steroids Horm Sci. 2015; 6 (1): 1000149. DOI:10.4172/2157-7536.1000149.; Mager D.E., Lin S.X., Blum R.A. et al. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J. Clin. Pharmacol. 2003; 43 (11): 1216–1227. DOI:10.1177/0091270003258651.; Танин И.Ю., Иванова Л.А., Король И.В. и др. Принципы назначения глюкокортикостероидов у пациентов с CОVID-19. Вестник современной клинической медицины. 2022; 15 (2): 103–109. DOI:10.20969/VSKM.2022.15(2).103-109.; RECOVERY Collaborative Group, Horby P. et al. Dexamethasone in hospitalized patients with COVID‐19. N. Engl. J. Med. 2021; 384: 693–704. DOI:10.1056/NEJMoa2021436.; Rygаrd S.L., Butler E., Granholm A. et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018; 44 (7): 1003–1016. DOI:10.1007/s00134-018-5197-6.; Salton F., Confalonieri P., Meduri G.U.et al. Theory and practice of glucocorticoids in COVID-19: getting to the heart of the matter-A critical review and viewpoints. Pharmceuticals (Basel). 2023; 16 (7): 924. DOI:10.3390/ph16070924.; Selye H. A syndrome produced by diverse nocuous agents. 1936. J. Neuropsychiatry Clin. Neurosci. 1998; 10 (2):230 231. DOI:10.1038/138032a.; Russell G., Lightman S. The human stress response. Nat. Rev. Endocrinol. 2019; 15 (9): 525–534. DOI:10.1038/s41574-019-0228-0.; Marik P.E., Pastores S.M., Annane D. et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med. 2008; 36 (6): 1937–1949. DOI:10.1097/CCM.0b013e31817603ba.; Annane D., Pastores S.M., Arlt W. et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a multispecialty task force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2017; 43 (12): 1781–1792. DOI:10.1007/s00134-017-4914-x.; Meduri G.U., Chrousos G.P. General adaptation in critical illness: glucocorticoid receptor-alpha master regulator of homeostatic corrections. Front. Endocrinol. (Lausanne). 2020. 11: 161. DOI:10.3389/fendo.2020.00161.; Harris L.K., Crannage A.J. Corticosteroids in community-acquired pneumonia: a review of current literature. J. Pharm. Technol. 2021; 37 (3): 152–160. DOI:10.1177/8755122521995587.; Mueller C., Blum C.A., Trummler M. et.al. Association of adrenal function and disease severity in community-acquired pneumonia. PLoS One. 2014; 9 (6): e99518. DOI:10.1371/journal.pone.0099518.; Beishuizen A., Thijs L.G., Vermes I. Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Crit. Care. 2002; 6 (5): 434–438. DOI:10.1186/cc1530.; Draghici S., Nguyen T.M., Sonna L.A. et al. COVID-19: Disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases. Bioinformatics. 2021; 37 (17): 2691–2698. DOI:10.1093/bioinformatics/btab163.; Харитонов М.А., Рудаков Ю.В., Салухов В.В., Волошин Н.И. Роль сурфактанта в патогенезе бронхолегочной патологии. Медицинский Совет. 2023; (20): 52. DOI:10.21518/ms2023-340.; Young A., Marsh S. Steroid use in critical care. BJA Educ. 2018; 18 (5): 129–134. DOI:10.1016/j.bjae.2018.01.005.; Lansbury L., Rodrigo C., Leonardi-Bee J. et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst. Rev. 2019; 2 (2): Cd010406. DOI:10.1002/14651858.CD010406.; Torres A., Sibila O., Ferrer M. et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313 (7): 677–686. DOI:10.1001/jama.2015.88.; Martin-Loeches I., Torres A., Nagavci B. et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur. Respir J. 2023; 61 (4): 2200735. DOI:10.1183/13993003.00735-2022.; Evans L., Rhodes A., Alhazzani W. et al Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47 (11): 1181–1247. DOI:10.1007/s00134-021-06506-y.; Chaudhuri D., Nei A.M., Rochwerg B. et al. 2024 focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit. Care Med. 2024; 52 (5): e219–233. DOI:10.1097/CCM.0000000000006172.; Cilloniz C., Ferrer M., Liapikou A. et.al. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur. Respir. J. 2018; 51 (3): 1702215. DOI:10.1183/13993003.02215-2017.; Салухов В.В., Волошин Н.И., Шперлинг М.И. Эффективность применения различных схем системной противовоспалительной терапии глюкокортикоидами при развитии острого ЛПС-индуцированного повреждения легких в эксперименте. Известия Российской Военно-медицинской академии. 2022; 41 (2): 111–116. DOI:10.17816/rmmar104619.; Hong S., Jian C., Wang H. Effects of different doses of methylprednisolone therapy on acute respiratory distress syndrome: results from animal and clinical studies. BMC Pulm. Med. 2022; 22 (1): 348. DOI:10.1186/s12890-022-02148-y.; Chaudhuri D., Sasaki K., Karkar A. et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021; 47 (5): 521–537. DOI:10.1007/s00134-021-06394-2; Tasaka S., Ohshimo S., Takeuchi M. et al. ARDS clinical practice guideline 2021. J. Intensive Care. 2022; 10 (1): 32. DOI:10.1186/s40560-022-00615-6.; Meduri G.U., Annane D., Confalonieri M. et. al. Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS. Intensive Care Med. 2020; 46 (12): 2284–2296. DOI:10.1007/s00134-020-06289-8.; Vandewalle J., Libert C. Glucocorticoids in sepsis: to be or not to be. Front. Immunol. 2020; 11: 1318. DOI:10.3389/fimmu.2020.01318.; Villar J., Ferrando C., Martínez D. et al Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 2020; 8: 267–276. DOI:10.1016/s2213-2600(19)30417-5.; Meduri G.U., Headley A.S., Golden E. et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998; 280 (2): 159–165. DOI:10.1001/jama.280.2.159.; Meduri G.U., Golden E., Freire A.X. et al. Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest. 2007; 131 (4): 954–959. DOI:10.1378/chest.06-2100.; Meduri G.U., Shih M.C., Bridges L. et al. Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022; 48 (8): 1009–1023. DOI:10.1007/s00134-022-06684-3.; Dequin P.F., Meziani F., Quenot J.P. et al. Hydrocortisone in severe community-acquired pneumonia. N. Engl. J. Med. 2023; 388 (21): 1931–1941. DOI:10.1056/NEJMoa2215145.; Metlay J.P., Waterer G.W. Time to treat severe community-acquired pneumonia with steroids? N. Engl. J. Med. 2023; 388 (21): 2001–2002. DOI:10.1056/NEJMe2302544.; Pitre T., Abdali D., Chaudhuri D. et al. Corticosteroids in community-acquired bacterial pneumonia: a systematic review, pairwise and dose-response meta-analysis. J. Gen. Intern. Med. 2023; 38 (11): 2593–2606. DOI:10.1007/s11606-023-08203-6.; Gu X., Yang P., Yu L.et al. Glucocorticoids can reduce mortality in patients with severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Research Square. (Version 1). [Preprint. Posted: 2023, Nov. 10]. DOI:10.21203/rs.3.rs-3576792/v1.; https://journal.pulmonology.ru/pulm/article/view/4662

Availability: https://journal.pulmonology.ru/pulm/article/view/4662
https://doi.org/10.18093/0869-0189-2024-34-6-775-787

Steroid myopathy in patients with myasthenia gravis: a literature review ; Стероидная миопатия у пациентов с аутоиммунной миастенией: обзор литературы

Authors: S. A. Zaytsevskaya, N. A. Suponeva, K. V. Antonova, D. A. Grishina, A. M. Narbut, С. А. Зайцевская, Н. А. Супонева, К. В. Антонова, Д. А. Гришина, А. М. Нарбут

Contributors: The work was performed without external funding, Работа выполнена без спонсорской поддержки

Source: Neuromuscular Diseases; Том 14, № 3 (2024); 90-101 ; Нервно-мышечные болезни; Том 14, № 3 (2024); 90-101 ; 2413-0443 ; 2222-8721

Subject Terms: глюкокортикостероиды, myasthenia gravis, glucocorticoids, аутоиммунная миастения

File Description: application/pdf

Relation: https://nmb.abvpress.ru/jour/article/view/623/400; Bowyer S., Lamothe M., Hollister J. Steroid myopathy: Incidence and detection in a population with asthma. J Allergy Clin Immunol 1985;76(2):234–42. DOI:10.1016/0091-6749(85)90708-0; Dubois E. Triamcinolone in the treatment of systemic lupus erythematosus. J Am Med Assoc 1958;167(13):1590–9. DOI:10.1001/jama.1958.02990300016004; Perkoff G., Silber R., Tyler F. et al. Studies in disorders of muscle. XII. Myopathy due to the administration of therapeutic amounts of 17-hydroxycorticosteroids. Am J Med 1959;26(6):891–8. DOI:10.1016/0002-9343(59)90211-6; Narayanaswami P., Sanders D., Wolfe G. et al. International Consensus Guidance for Management of Myasthenia Gravis. Neurology 2021;96(3):114–22. DOI:10.1212/ WNL.0000000000011124; Sussman J., Farrugia M., Maddison P. et al. Myasthenia gravis: Association of British neurologists’ management guidelines. Pract Neurol 2015;15(3):199–206. DOI:10.1136/practneurol-2015-001126; Murai H., Utsugisawa K., Motomura M. et al. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome. Clinical and Experimental Neuroimmunology 2023;14:19–27.DOI:10.1111/cen3.12739; Wiendl H., Abicht A., Chan A. et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 2023;16:17562864231213240. DOI:10.1177/17562864231213240; Gupta A., Gupta Y. Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 2013;17(5):913–6. DOI:10.4103/2230-8210.117215; Batchelor T., Taylor L., Thaler H. et al. Steroid myopathy in cancer patients. Neurology 1997;48(5):1234–8. DOI:10.1212/WNL.48.5.1234; Wu K., Michalski A., Cortes D. et al. Glucocorticoid-induced myopathy in people with asthma: A systematic review. J Asthma 2022;59(7):1396–409. DOI:10.1080/02770903.2021.1926488; Buttgereit F., Da Silva J., Boers M. et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61(8):718–22. DOI:10.1136/ard.61.8.718; Al Efraij K., Johnson K., Wiebe D. et al. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma 2019;56(12):1334–46. DOI:10.1080/02770903.2018.1539100; Esteves G., Mazzolani B., Smaira F. et al. Nutritional recommendations for patients undergoing prolonged glucocorticoid therapy. Rheumatol Adv Pract 2022;6(2):rkac029. DOI:10.1093/rap/rkac029; Nagashima M., Takahashi D., Mizushima T. et al. Effects of exercise in patients with connective tissue disease receiving highdose glucocorticoids: A pilot prospective cohort study. Eur J Appl Physiol 2021;121(8):2253–63. DOI:10.1007/s00421-021-04697-2; Zamecnik J., Vesely D., Jakubicka B. et al. Atrophy of type II fibres in myasthenia gravis muscle in thymectomized patients: Steroid-induced change with prognostic impact. J Cell Mol Med 2009;13(8 B):2008–18. DOI:10.1111/j.1582-4934.2008.00431.x; Berr C., Stieg M., Deutschbein T. et al. Persistence of myopathy in Cushing’s syndrome: Evaluation of the German Cushing’s Registry. Eur J Endocrinol 2017;176(6):737–46. DOI:10.1530/EJE-16-0689; Bolland M., Holdaway I., Berkeley J. et al. Mortality and morbidity in Cushing’s syndrome in New Zealand. Clin Endocrinol (Oxf) 2011;75(4):436–42. DOI:10.1111/j.1365-2265.2011.04124.x; Giraldi F., Moro M., Cavagnini F. Gender-related differences in the presentation and course of Cushing’s disease. J Clin Endocrinol Metab 2003;88(4):1554–8. DOI:10.1210/jc.2002-021518; Macedo A., Almeida T., Massini D. et al. Effects of exercise training on glucocorticoid-induced muscle atrophy: Literature review. Steroids 2023;195(5):109240. DOI:10.1016/j.steroids.2023.109240; Costa M., Violato N., Taboga S. et al. Reduction of insulin signalling pathway IRS-1/IRS-2/AKT/mTOR and decrease of epithelial cell proliferation in the prostate of glucocorticoid-treated rats. Int J Exp Pathol 2012;93(3):188–95. DOI:10.1111/j.1365-2613.2012.00817.x; Macedo A., Krug A., Herrera N. et al. Low-intensity resistance training attenuates dexamethasone-induced atrophy in the flexor hallucis longus muscle. J Steroid Biochem Mol Biol 2014;143:357–64. DOI:10.1016/j.jsbmb.2014.05.010; Ma K., Mallidis C., Bhasin S. et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Metab 2003;285(2):363–71. DOI:10.1152/ajpendo.00487.2002; Cho J., Fournier M., Da X. et al. Time course expression of Foxo transcription factors in skeletal muscle following corticosteroid administration. J Appl Physiol 2010;108(1):137–45. DOI:10.1152/japplphysiol.00704.2009; Fappi A., De Carvalho Neves J., Sanches L. et al. Skeletal muscle response to deflazacort, dexamethasone and methylprednisolone. Cells 2019;8(5):406. DOI:10.3390/cells8050406; Kanda F., Okuda S., Matsushita T. et al. Steroid myopathy: Pathogenesis and effects of growth hormone and insulin-like growth factor-I administration. Horm Res Paediatr 2001;56(1):24–8. DOI:10.1159/000048130; Afifi A., Bergman R., Harvey J. Steroid myopathy. Clinical, histologic and cytologic observations. Johns Hopkins Med J 1968;123(4):158–73.; Engel A. Electron microscopic observations in thyrotoxic and corticosteroid-induced myopathies. Mayo Clin Proc 1966;41(11):785–96.; Walsh G., DeVivo D., Olson W. Histochemical and ultrastructural changes in rat muscle. Occurrence following adrenal corticotrophic hormone, glucocorticoids, and starvation. Arch Neurol 1971;24(1):83–93. DOI:10.1001/archneur.1971.00480310111012; Horber F., Hoppeler H., Herren D. et al. Altered skeletal muscle ultrastructure in renal transplant patients on prednisone. Kidney Int 1986;30(3):411–6. DOI:10.1038/ki.1986.199; Vallet B., Fourrier F., Hurtevent J. et al. Myasthenia gravis and steroid-induced myopathy of the respiratory muscles. Intensive Care Med 1992;18:424–6. DOI:10.1007/BF01694346; Waclawik A., Sufit R., Beinlich B. et al. Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium. Neuromuscul Disord 1992;2(1):19–26. DOI:10.1016/0960-8966(92)90022-x; Hatakenaka M., Soeda H., Okafuji T. et al. Steroid myopathy: Evaluation of fiber atrophy with T2 relaxation time – rabbit and human study. Radiology 2006;238(2):650–7. DOI:10.1148/radiol.2381041720; Williams T., O’Hehir R., Czarny D. et al. Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis 1988;137(2):460–3. DOI:10.1164/ajrccm/137.2.460; Khaleeli A., Edwards R., Gohil K. et al. Corticosteroid myopathy: A clinical and pathological study. Clin Endocrinol 1983;18(2):155–66. DOI:10.1111/j.1365-2265.1983.tb03198.x; Minetto M., D’Angelo V., Arvat E. et al. Diagnostic work-up in steroid myopathy. Endocrine 2018;60:219–23. DOI:10.1007/s12020-017-1472-5; Weber M., Krakowski-Roosen H., Schröder L. et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 2009;48(1):116–24. DOI:10.1080/02841860802130001; D’Antona G., Pellegrino M., Adami R. et al. The effect of ageing and immobilization on structure and function of human skeletal muscle fibres. J Physiol 2003;552(2):499–511. DOI:10.1113/jphysiol.2003.046276; Brooke M., Engel W. The histographic analysis of human muscle biopsies with regard to fiber types. Neurology 1969;19(5):469–77. DOI:10.1212/WNL.19.5.469; Russell D. Histological changes in the striped muscles in myasthenia gravis. J Pathol Bacteriol 1953;65(2):279–89. DOI:10.1002/path.1700650202; Fenichel G. Muscle lesions in myasthenia gravis. Ann NY Acad Sci 1966;135(1):60–7. DOI:10.1111/j.1749-6632.1966.tb45463.x; Martignago S., Fanin M., Albertini E. et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 2009;35(1):103–10. DOI:10.1111/j.1365-2990.2008.00965.x; Pereira R., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41–4. DOI:10.1016/j.jbspin.2010.02.025; Ammini A., Tandon N., Gupta N. et al. Etiology and clinical profile of patients with Cushing’s syndrome: A single center experience. Indian J Endocrinol Metab 2014;18(1):99–105. DOI:10.4103/2230-8210.126586; Olafsson E., Jones H., Guay A. et al. Myopathy of endogenous Cushing’s syndrome: A review of the clinical and electromyographic features in 8 patients. Muscle Nerve 1994;17(6):692, 693. DOI:10.1002/mus.880170625; Silver E., Ochoa W. Glucocorticoid-Induced myopathy in a patient with systemic lupus erythematosus (SLE): A case report and review of the literature. Am J Case Rep 2018;19(3):277–83. DOI:10.12659/ajcr.906377; Minetto M., Lanfranco F., Motta G. et al. Steroid myopathy: Some unresolved issues. J Endocrinol Invest 2011;34(5):370–5. DOI:10.1007/BF03347462; Schakman O., Kalista S., Barbé C. et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45(10): 2163–72. DOI:10.1016/j.biocel.2013.05.036; Haran M., Schattner A., Kozak N. et al. Acute steroid myopathy: A highly overlooked entity. QJM 2018;111(5):307–11. DOI:10.1093/qjmed/hcy031; Lacomis D., Smith T., Chad D. Acute myopathy and neuropathy in status asthmaticus: Case report and literature review. Muscle Nerve 1993;16(1):84–90. DOI:10.1002/mus.880160114; Knox A., Mascie-Taylor B., Muers M. Acute hydrocortisone myopathy in acute severe asthma. Thorax 1986;41(5):411, 412. DOI:10.1136/thx.41.5.411; Van Marle W., Woods K. Acute hydrocortisone myopathy. BMJ 1980;281(6235):271, 272. DOI:10.1136/bmj.281.6235.271-a; Panegyres P., Squier M., Mills K. et al. Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis. J Neurol Neurosurg Psychiatry 1993;56(6):702–4. DOI:10.1136/jnnp.56.6.702.; Джериева В.С., Бровкина С.С., Волкова Н.И. Сочетание кортикостероид-индуцированной миопатии и myasthenia gravis: трудности диагностики. FOCUS Эндокринология 2020;1(1):66–70. DOI:10.47407/ef2020.1.1.0009; Lotan I., Hellmann M., Wilf-Yarkoni A. et al. Exacerbation of myasthenia gravis following corticosteroid treatment: What is the evidence? A systematic review. Neurology 2021;268:4573–86. DOI:10.1007/s00415-020-10264-0; Simon N. A new diagnostic tool for the detection of steroid myopathy. Clin Neurophysiol 2019;130(8):1407, 1408. DOI:10.1016/j.clinph.2019.05.019; Minetto M., Lanfranco F., Botter A. et al. Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing’s disease. Eur J Endocrinol 2011;164(6):985–93. DOI:10.1530/EJE-10-1169; Yoshikawa N., Yamamoto M., Kuribara-Souta A. et al. Amino acid profile in 18 patients with rheumatic diseases treated with glucocorticoids and BCAAs. J Nutr Sci Vitaminol (Tokyo) 2021;67(3):180–8. DOI:10.3177/jnsv.67.180; Stålberg E., Sonoo M. Assessment of variability in the shape of the motor unit action potential, the “jiggle”, at consecutive discharges. Muscle Nerve 1994;17(10):1135–44. DOI:10.1002/mus.880171003; Juel V. Clinical neurophysiology of neuromuscular junction disease. In: Handbook of Clinical Neurology. Ed. by K.H. Levin and P. Chauvel. Elsevier B.V., 2019. Pp. 291–303. DOI:10.1016/B978-0-444-64142-7.00055-2; Somnier F., Skeie G., Aarli J. et al. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. Eur J Neurol 1999;6(5):555–63. DOI:10.1046/j.1468-1331.1999.650555.x; Санадзе А.Г., Сиднев Д.В., Галкина О.И. и др. Миастеническая миопатия. Журнал неврологии и психиатрии им. С.С. Корсакова 2007;107(9):11–6.; Санадзе А.Г., Гильванова О.В. Миастения и мышечные атрофии. Журнал неврологии и психиатрии им. С.С. Корсакова 2021;121(2):79–87. DOI:10.17116/jnevro202112102179; Lexell J., Henriksson-larsén K., Sjöström M. Distribution of different fibre types in human skeletal muscles 2. A study of cross-sections of whole m. vastus lateralis. Acta Physiol Scand 1983;117(1):115–22. DOI:10.1111/j.1748-1716.1983.tb07185.x; Minetto M., Botter A., Lanfranco F. et al. Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. J Clin Endocrinol Metab 2010;95(4):1663–71. DOI:10.1210/jc.2009-2161; Beck R. Muscle fiber conduction velocity. In: Wiley Encyclopedia of Biomedical Engineering. Wiley, 2006. DOI:10.1002/9780471740360.ebs0306; Blijham P., Ter Laak H., Schelhaas H. et al. Relation between muscle fiber conduction velocity and fiber size in neuromuscular disorders. J Appl Physiol 2006;100(6):1837–41. DOI:10.1152/japplphysiol.01009.2005; Kemink S., Frijns J., Hermus A. et al. Body composition determined by six different methods in women bilaterally adrenalectomized for treatment of Cushing’s disease. J Clin Endocrinol Metab 1999;84(11):3991–9. DOI:10.1210/jcem.84.11.6143; Hosono O., Yoshikawa N., Shimizu N. et al. Quantitative analysis of skeletal muscle mass in patients with rheumatic diseases under glucocorticoid therapy – comparison among bioelectrical impedance analysis, computed tomography, and magnetic resonance imaging. Mod Rheumatol 2015;25:257–63. DOI:10.3109/14397595.2014.935078; Martucci M., McIlduff C., Shin C. et al. Quantitative ultrasound of muscle can detect corticosteroid effects. Clin Neurophysiol 2019;130(8):1460–4. DOI:10.1016/j.clinph.2019.04.709; Minetto M., Caresio C., Salvi M. et al. Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease. J Endocrinol Invest 2019;42(7):757–68. DOI:10.1007/s40618-018-0979-9; Dunlap K., Steiner J., Hickner R. et al. The duration of glucocorticoid treatment alters the anabolic response to high-force muscle contractions. J Appl Physiol 2023;135(1):183–95. DOI:10.1152/japplphysiol.00113.2023; Braith R., Welsch M., Mills R. et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sport Exerc 1998;30(4):483–9. DOI:10.1097/00005768-199804000-00003; Horber F., Scheidegger J., Grunig B. et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab 1985;61(1):83–8. DOI:10.1210/jcem-61-1-83; LaPier T. Glucocorticoid-induced muscle atrophy. J Cardiopulm Rehabil 1997;17(2):76–84. DOI:10.1097/00008483-199703000-00002; Yoshikawa N., Shimizu N., Uehara M. et al. The effects of bolus supplementation of branched-chain amino acids on skeletal muscle mass, strength, and function in patients with rheumatic disorders during glucocorticoid treatment. Mod Rheumatol 2017;27(3):508–17. DOI:10.1080/14397595.2016.1213480; Ulla A., Uchida T., Miki Y. et al. Morin attenuates dexamethasonemediated oxidative stress and atrophy in mouse C2C12 skeletal myotubes. Arch Biochem Biophys 2021;704:108873. DOI:10.1016/j.abb.2021.108873; Lee H., Kim Y., Nirmala F. et al. Chrysanthemum zawadskil Herbich attenuates dexamethasone-induced muscle atrophy through the regulation of proteostasis and mitochondrial function. Biomed Pharmacother 2021;136:111226. DOI:10.1016/j.biopha.2021.111226; Shang Y., Kuang M., Wang Z. et al. An ultrashort peptide-based supramolecular hydrogel mimicking IGF-1 to alleviate glucocorticoid-induced sarcopenia. ACS Appl Mater Interfaces 2020;12(31):34678–88. DOI:10.1021/acsami.0c09973; Chen H., Ma J., Ma X. Administration of tauroursodeoxycholic acid attenuates dexamethasone-induced skeletal muscle atrophy. Biochem Biophys Res Commun 2021;570:96–102. DOI:10.1016/j.bbrc.2021.06.102; Lee M., Jeong H., Kim M.-J. et al. Nutrients against glucocorticoidinduced muscle atrophy. Foods 2022;11(5):687. DOI:10.3390/foods11050687; Труш В.В., Соболев В.И. Оценка эффективности β2-адреноагониста формотерола в компенсации электрофизиологических проявлений стероидной миопатии в модельных экспериментах на животных. Патологическая физиология и экспериментальная терапия 2019;(3):35–47. DOI:10.25557/0031-2991.2019.03.35-47; Труш В.В., Соболев В.И. Эффективность α-липоевой кислоты в компенсации электрофизиологических проявлений стероидной миопатии в экспериментах на животных. Экспериментальная и клиническая фармакология 2021;84(12):20–8. DOI:10.30906/0869-2092-2021-84-12-20; Труш В.В., Соболев В.И. Модуляция альфакальцидолом некоторых электрофизиологических проявлений стероидной миопатии в модельных экспериментах на животных. Ученые записки Крымского федерального университета им. В.И. Вернадского. Биология. Химия 2022;8(2):198–217.; Miyakoshi N., Sasaki H., Kasukawa Y. et al. Effects of a vitamin D analog, alfacalcidol, on bone and skeletal muscle in glucocorticoidtreated rats. Biomed Res 2010;31(6):329–36. DOI:10.2220/biomedres.31.329; Ito S., Harada A., Kasai T. et al. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: An investigation using a patient database. Geriatr Gerontol Int 2014;141:122–8. DOI:10.1111/ggi.12222; Wang X., Yang X., Wang R. et al. Leucine alleviates dexamethasoneinduced suppression of muscle protein synthesis via synergy involvement of mTOR and AMPK pathways. Biosci Rep 2016;36(3):e00346. DOI:10.1042/BSR20160096; Yamamoto D., Maki T., Herningtyas E. et al. Branched-chain amino acids protect against dexamethasone-induced soleus muscle atrophy in rats. Muscle Nerve 2010;41(6):819–27. DOI:10.1002/mus.21621; Cochet C., Belloni G., Buondonno I. et al. The role of nutrition in the treatment of sarcopenia in old patients: From restoration of mitochondrial activity to improvement of muscle performance, a systematic review. Nutrients 2023;15(17):3703. DOI:10.3390/nu15173703; https://nmb.abvpress.ru/jour/article/view/623

Availability: https://nmb.abvpress.ru/jour/article/view/623
https://doi.org/10.17650/2222-8721-2024-14-3-90-101